Keywords
Treatment
Glucocorticoids
Mineralocorticoids
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Synthesize therapeutic options for Addison's Disease (AD), focusing on hormonal replacement with glucocorticoids and mineralocorticoids. Methods: Integrative review on PubMed. After the search, 173 articles were identified; 13 were selected. Results: Modern therapy and education are crucial for functional living with AD. Dual-release hydrocortisone (DR-HC) improves bone health compared to conventional therapy. Transitioning from cortisone acetate to modified-release hydrocortisone benefits blood pressure control. Patients on glucocorticoid replacement have a higher risk of fractures. Genetic diagnosis is crucial, especially in pediatric cases. Conclusion: Standard treatment for Primary Adrenal Insufficiency involves hydrocortisone and fludrocortisone, but innovative approaches show benefits. Long-term clinical trials are necessary to validate new therapies, identify reliable markers, and optimize dosages.
References
BARTHEL A, et al. An Update on Addison's Disease. Exp Clin Endocrinol Diabetes, 2019; 127(2-03): 165-175.
BETTERLE C, et al. Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults. Journal of Endocrinological Investigation, 2019; 42(12): 1407–1433.
BAKER PR, et al. Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf), 2012; 76(5): 617-24.
BUONOCORE F e JOHN CA. Primary adrenal insufficiency: New genetic causes and their long‐term consequences. Clinical Endocrinology, 2020; 92(1): 11-20.
CECCATO F, et al. Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency. J Endocrinol Invest, 2023; 46(1): 111-122.
ESPIARD S, et al. Improved urinary cortisol metabolome in Addison disease: A prospective trial of dual-release hydrocortisone. The Journal of Clinical Endocrinology & Metabolism, 2021; 106(3): 814-825.
FICHNA M, et al. Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency. Hormone and Metabolic Research, 2020; 52(5): 322-328.
GUNNA S, et al. Etiology, clinical characteristics and mortality among Indian patients with Addison's disease. Endocr Connect, 2023; 12(3): e220439.
HELLESEN A, et al. Autoimmune Addison’s disease – An update on pathogenesis. Annales d'endocrinologie, 2018; 79(3): 157-163.
HUSEBYE ES, et al. Consensus statement on the diagnosis, treatment and follow‐up of patients with primary adrenal insufficiency. Journal of internal medicine, 2014; 275(2): 104-115.
LI L, et al. Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis. Endocrine, 2021; 74(1): 29-37.
NAPIER C, et al. Residual Adrenal Function in Autoimmune Addison's Disease-Effect of Dual Therapy With Rituximab and Depot Tetracosactide. The Journal of clinical endocrinology and metabolism, 2020; 105(4): e1250–e1259a.
NAPIER C, et al. Natural history of adrenal steroidogenesis in autoimmune Addison’s disease following diagnosis and treatment. The Journal of Clinical Endocrinology & Metabolism, 2020; 105(7): 2322-2330b.
MANSO J, et al. The natural history of autoimmune Addison's disease with a non-classical presentation: a case report and review of the literature. Clin Chem Lab Med, 2018; 56(6): 896-900.
MOSCA AM, et al. Addison's Disease: A Diagnosis Easy to Overlook. Cureus, 2021; 13(2): e13364.
SAVERINO S, FALORNI A. Autoimmune Addison's disease. Best Pract Res Clin Endocrinol Metab, 2020; 34(1): 101379.
SCHRÖDER W, et al. Anastomotic Techniques and Associated Morbidity in Total Minimally Invasive Transthoracic Esophagectomy: Results From the EsoBenchmark Database. Ann Surg, 2019; 270(5): 820-826.
SMANS LC e ZELISSEN PM. Recuperação parcial da função adrenal em um paciente com doença de Addison autoimune. J Endocrinol Invest, 2008; 31(7): 672-4.
THUILLIER P e KERLAN V. Maladies surrénaliennes infracliniques: cas du phéochromocytome silencieux et de la maladie d'Addison infra-clinique [Subclinical adrenal diseases: silent pheochromocytoma and subclinical Addison's disease]. Ann Endocrinol (Paris), 2012; 73(1): S45-54.
WANG Z, et al. Comparison of hand-sewn versus mechanical esophagojejunostomy in totally laparoscopic total gastrectomy: study protocol for a randomized controlled trial. Trials, 2022; 22(1): 219.